FDA approves first biosimilar for treatment of cancer
On Sept. 14, the U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi…
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.